{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:38Z","timestamp":1783908518045,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01 DK112271"],"award-info":[{"award-number":["U01 DK112271"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43 TW011544"],"award-info":[{"award-number":["D43 TW011544"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05280-2","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T07:05:56Z","timestamp":1775545556000},"page":"14587-14594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and tolerability of the ACE-inhibitor lisinopril among Nigerian adults with HIV: preliminary pilot data from a randomized clinical trial"],"prefix":"10.1007","volume":"399","author":[{"given":"Faisal S.","family":"Dankishiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman J.","family":"Wudil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baba M.","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aima A.","family":"Ahonkhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Burgner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishatu M.","family":"Nalado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud U.","family":"Sani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliyu","family":"Abdu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan E.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muktar H.","family":"Aliyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. William","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"1","key":"5280_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3436-y","volume":"20","author":"MH Aliyu","year":"2019","unstructured":"Aliyu MH et al (2019) Optimal management of HIV- positive\u00a0adults at risk for kidney disease in Nigeria (Renal Risk Reduction \u201cR3\u201d Trial): protocol and study design. Trials 20(1):341. https:\/\/doi.org\/10.1186\/s13063-019-3436-y","journal-title":"Trials"},{"issue":"4","key":"5280_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.1026","volume":"156","author":"H Asad","year":"2019","unstructured":"Asad H, Gohar A (2019) Incidence of angiotensin-converting enzyme-associated angioedema among African Americans compared to other races. Chest 156(4):A1123. https:\/\/doi.org\/10.1016\/j.chest.2019.08.1026","journal-title":"Chest"},{"issue":"3","key":"5280_CR3","first-page":"461","volume":"66","author":"DP Bicket","year":"2002","unstructured":"Bicket DP (2002) Using ACE inhibitors appropriately. Am Fam Physician 66(3):461\u2013469","journal-title":"Am Fam Physician"},{"issue":"3","key":"5280_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00228-020-03018-4","volume":"77","author":"S B\u0153uf-Gibot","year":"2021","unstructured":"B\u0153uf-Gibot S et al (2021) Benefits and adverse effects of ACE inhibitors in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis. Eur J Clin Pharmacol 77(3):321\u2013329. https:\/\/doi.org\/10.1007\/s00228-020-03018-4","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"5280_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11908-009-0069-4","volume":"11","author":"LA Bruggeman","year":"2009","unstructured":"Bruggeman LA, Bark C, Kalayjian RC (2009) HIV and the kidney. Curr Infect Dis Rep 11(6):479\u2013485. https:\/\/doi.org\/10.1007\/s11908-009-0069-4","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"5280_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-67703-5","volume":"14","author":"A Chen","year":"2024","unstructured":"Chen A et al (2024) Hypertension among people living with human immunodeficiency virus in sub-Saharan Africa: a systematic review and meta-analysis. Sci Rep 14(1):16858. https:\/\/doi.org\/10.1038\/s41598-024-67703-5","journal-title":"Sci Rep"},{"issue":"3","key":"5280_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.20411\/pai.v2i3.207","volume":"2","author":"LR Cockerham","year":"2017","unstructured":"Cockerham LR et al (2017) A randomized controlled trial of lisinopril to decrease lymphoid fibrosis in antiretroviral-treated, HIV-infected individuals. Pathogens & Immunity 2(3):310\u2013334. https:\/\/doi.org\/10.20411\/pai.v2i3.207","journal-title":"Pathogens & Immunity"},{"key":"5280_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2025.1664354","volume":"6","author":"C Day","year":"2025","unstructured":"Day C et al (2025) Risk factors for angiotensin converting enzyme inhibitor angioedema in a South African population. Front Allergy 6:1664354. https:\/\/doi.org\/10.3389\/falgy.2025.1664354","journal-title":"Front Allergy"},{"key":"5280_CR9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/VHRM.S363051","volume":"18","author":"AT Gelaye","year":"2022","unstructured":"Gelaye AT, Seid MA, Baffa LD (2022) Angiotensin-converting enzyme inhibitor dose optimization and its associated factors at Felege Hiwot Comprehensive Specialized Hospital, Bahir Dar, Ethiopia. Vasc Health Risk Manag 18:481\u2013493. https:\/\/doi.org\/10.2147\/VHRM.S363051","journal-title":"Vasc Health Risk Manag"},{"key":"5280_CR10","doi-asserted-by":"publisher","unstructured":"Gupta SK et al\u00a0(2009) Proteinuria, CrCl, and immune activation in antiretroviral-na\u00efve HIV-infected subjects. J Infect Dis\u00a0200(4):614\u2013618. Available at: https:\/\/doi.org\/10.1086\/600890","DOI":"10.1086\/600890"},{"key":"5280_CR11","unstructured":"Hill RD, Vaidya PN (2024) Angiotensin II receptor blockers (ARB). In: StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537027\/. Accessed: 15 July 2024"},{"issue":"8","key":"5280_CR12","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jch.14695","volume":"25","author":"Y Hu","year":"2023","unstructured":"Hu Y et al (2023) Angiotensin-converting enzyme inhibitor induced cough compared with placebo, and other antihypertensives: a systematic review, and network meta-analysis. Journal of Clinical Hypertension (Greenwich, Conn.) 25(8):661\u2013688. https:\/\/doi.org\/10.1111\/jch.14695","journal-title":"Journal of Clinical Hypertension (Greenwich, Conn.)"},{"issue":"9","key":"5280_CR13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.5624","volume":"11","author":"F Jamshed","year":"2019","unstructured":"Jamshed F et al (2019) Demographic and clinical characteristics of patients presenting with angiotensin-converting enzyme inhibitors induced cough. Cureus 11(9):e5624. https:\/\/doi.org\/10.7759\/cureus.5624","journal-title":"Cureus"},{"key":"5280_CR14","doi-asserted-by":"publisher","unstructured":"Kidney International (2022) Expression of concern from the KI Editors: \u201cApolipoprotein-1 risk variants and associated kidney phenotypes in an adult HIV cohort in Nigeria\u201d [Kidney International, July 2021, Pages 146\u2013154] and \u201cAPOL1-associated kidney disease in northern Nigerians with treated HIV infection\u201d [Kidney International, July 2021, Pages 19\u201321] 101(1):188. Available at: https:\/\/doi.org\/10.1016\/j.kint.2021.11.003","DOI":"10.1016\/j.kint.2021.11.003"},{"issue":"4","key":"5280_CR15","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.kint.2022.06.021","volume":"102","author":"A Lucas","year":"2022","unstructured":"Lucas A, Wyatt CM (2022) HIV at 40: kidney disease in HIV treatment, prevention, and cure. Kidney Int 102(4):740\u2013749. https:\/\/doi.org\/10.1016\/j.kint.2022.06.021","journal-title":"Kidney Int"},{"issue":"7","key":"5280_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040245","volume":"7","author":"A Mocroft","year":"2012","unstructured":"Mocroft A et al (2012) Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One 7(7):e40245. https:\/\/doi.org\/10.1371\/journal.pone.0040245","journal-title":"PLoS One"},{"key":"5280_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106081","volume":"78","author":"V Montinaro","year":"2020","unstructured":"Montinaro V, Cicardi M (2020) ACE inhibitor-mediated angioedema. Int Immunopharmacol 78:106081. https:\/\/doi.org\/10.1016\/j.intimp.2019.106081","journal-title":"Int Immunopharmacol"},{"issue":"14","key":"5280_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19148373","volume":"19","author":"M Na Takuathung","year":"2022","unstructured":"Na Takuathung M et al (2022) Adverse effects of angiotensin-converting enzyme inhibitors in humans: a systematic review and meta-analysis of 378 randomized controlled trials. Int J Environ Res Public Health 19(14):8373. https:\/\/doi.org\/10.3390\/ijerph19148373","journal-title":"Int J Environ Res Public Health"},{"issue":"1\u20132","key":"5280_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000353223","volume":"123","author":"II Ulasi","year":"2013","unstructured":"Ulasi II et al (2013) High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo People from South-Eastern Nigeria. Nephron Clin Pract 123(1\u20132):123\u2013128. https:\/\/doi.org\/10.1159\/000353223","journal-title":"Nephron Clin Pract"},{"key":"5280_CR20","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (2017) Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1. Available at: https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables. Accessed 15 July 2024"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05280-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05280-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:12Z","timestamp":1783907052000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05280-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5280"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05280-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the Institutional Review Board of Vanderbilt University Medical Center (FWA00005756) and the Ethics Committee of AKTH (FWA00026225). The study was registered with clinicaltrials.gov (NCT03201939) and the Pan African Clinical Trials Registry (PACTR201711002808414).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"We obtained informed consent from all individual participants included in the study. During the consent process, we explained to participants the purpose of the study, the study procedures, as well as potential risks and benefits of participating in the study. We ensured confidentiality of all participants\u2019 data and informed them about voluntariness of participation. We informed them they were free to withdraw at any time without any consequences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"We informed all the participants in this study that we will publish findings from the study and assured them that we will deidentify all data prior to publication to ensure confidentiality and anonymity.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}